Inventor
PAPAIOANNOU NIKOLAOS
US19 patents
⚠️ This page may combine multiple inventors who share the name “PAPAIOANNOU NIKOLAOS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
PFIZER
8 patentsUS9879022B2Jan 30, 2018
Bicyclic-fused heteroaryl or aryl compounds
PFIZER19 citations93
US9458168B2Oct 4, 2016
Bicyclic-fused heteroaryl or aryl compounds
PFIZER17 citations92
US11702424B2Jul 18, 2023
Bicyclic-fused heteroaryl or aryl compounds
PFIZER4 citations85
US10793579B2Oct 6, 2020
Bicyclic-fused heteroaryl or aryl compounds
PFIZER3 citations83
US10329302B2Jun 25, 2019
Bicyclic-fused heteroaryl or aryl compounds
PFIZER3 citations83
US10316018B2Jun 11, 2019
Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
PFIZER2 citations72
US10174000B2Jan 8, 2019
Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
PFIZER5 citations72
US12202836B2Jan 21, 2025
Bicyclic-fused heteroaryl or aryl compounds
PFIZER0 citations62
TAKEDA PHARMACEUTICALS CO
8 patentsUS11787796B2Oct 17, 2023
Plasma Kallikrein inhibitors and uses thereof
TAKEDA PHARMACEUTICALS CO4 citations72
US11370803B2Jun 28, 2022
Heteroaryl plasma kallikrein inhibitors
TAKEDA PHARMACEUTICALS CO5 citations71
US11352356B2Jun 7, 2022
Inhibitors of plasma kallikrein and uses thereof
TAKEDA PHARMACEUTICALS CO4 citations69
US11905285B2Feb 20, 2024
Inhibitors of plasma kallikrein and uses thereof
TAKEDA PHARMACEUTICALS CO0 citations62
US11168083B2Nov 9, 2021
Inhibitors of Plasma Kallikrein and uses thereof
TAKEDA PHARMACEUTICALS CO1 citations62
US12221441B2Feb 11, 2025
Plasma kallikrein inhibitors and uses thereof
TAKEDA PHARMACEUTICALS CO0 citations60
US12065448B2Aug 20, 2024
Heteroaryl plasma kallikrein inhibitors
TAKEDA PHARMACEUTICALS CO1 citations60
US12441724B2Oct 14, 2025
Inhibitors of plasma kallikrein and uses thereof
TAKEDA PHARMACEUTICALS CO0 citations58